Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2022

10-06-2021 | Ulcerative Colitis | Original Article

Patient-Reported Outcomes and Risk of Hospitalization and Readmission in Patients with Inflammatory Bowel Diseases

Authors: Nghia H. Nguyen, Xian Zhang, Millie D. Long, William J. Sandborn, Michael D. Kappelman, Siddharth Singh

Published in: Digestive Diseases and Sciences | Issue 6/2022

Login to get access

Abstract

Background and Aims

Patient-reported outcome measures (PROMs) provide a wholesome view of patient well-being. We conducted a retrospective cohort study to evaluate whether PROMs inform risk of unplanned healthcare utilization in patients with IBD.

Methods

We identified adult patients with IBD who completed at least two surveys in a large Internet-based cohort within 1 year. We evaluated the association between baseline patient characteristics, disease activity indices, medication use, and PROMs, assessed using NIH Patient-Reported Outcome Measurement Information System (PROMIS) and subsequent risk of incident hospitalization (at time of first follow-up) within 1 year, and readmission within 1 year (in patients with hospitalization at first follow-up), using multivariable logistic regression.

Results

Of 7902 patients with IBD (45.5 year, 72% females, 63% Crohn’s disease), 1377 (17.4%) were hospitalized within 1 year. Among PROMs, pain interference (adjusted OR per 5-point increase in PROMIS, 1.09; 95% CI 1.05–1.14), but not depression, anxiety, fatigue or sleep disturbance, was predictive of higher risk of hospitalization. Prior surgery or hospitalization, symptomatic disease, biologic, and corticosteroid use were also associated with higher risk of hospitalization. Of 521 patients hospitalized with IBD, 133 (25.5%) were readmitted within 1 year. Anxiety and pain interference were predictive of higher risk of readmission, whereas depression was associated with lower risk of readmission.

Conclusions

In a large Internet-based cohort study, PROMs may have a modest effect on modifying risk of unplanned healthcare utilization in patients with IBD, with pain interference being most consistently associated with increased risk of hospitalization and readmission.
Appendix
Available only for authorised users
Literature
1.
go back to reference GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5:17–30.CrossRef GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5:17–30.CrossRef
2.
go back to reference Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018;390:2769–2778.CrossRef Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018;390:2769–2778.CrossRef
3.
go back to reference Park KT, Ehrlich OG, Allen JI et al. The cost of inflammatory bowel disease: an initiative from the Crohn’s & Colitis Foundation. Inflamm Bowel Dis 2020;26:1–10.CrossRef Park KT, Ehrlich OG, Allen JI et al. The cost of inflammatory bowel disease: an initiative from the Crohn’s & Colitis Foundation. Inflamm Bowel Dis 2020;26:1–10.CrossRef
4.
go back to reference Peery AF, Crockett SD, Murphy CC et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 2019;156:254-272 e11.CrossRef Peery AF, Crockett SD, Murphy CC et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 2019;156:254-272 e11.CrossRef
5.
go back to reference Dieleman JL, Cao J, Chapin A et al. US health care spending by payer and health condition, 1996–2016. JAMA 2020;323:863–884.CrossRef Dieleman JL, Cao J, Chapin A et al. US health care spending by payer and health condition, 1996–2016. JAMA 2020;323:863–884.CrossRef
6.
go back to reference Nguyen NH, Khera R, Ohno-Machado L et al. Annual burden and costs of hospitalization for high-need, high-cost patients with chronic gastrointestinal and liver diseases. Clin Gastroenterol Hepatol 2018;16:1284-1292 e30.CrossRef Nguyen NH, Khera R, Ohno-Machado L et al. Annual burden and costs of hospitalization for high-need, high-cost patients with chronic gastrointestinal and liver diseases. Clin Gastroenterol Hepatol 2018;16:1284-1292 e30.CrossRef
7.
go back to reference Barnes EL, Kochar B, Long MD et al. Modifiable risk factors for hospital readmission among patients with inflammatory bowel disease in a nationwide database. Inflamm Bowel Dis 2017;23:875–881.CrossRef Barnes EL, Kochar B, Long MD et al. Modifiable risk factors for hospital readmission among patients with inflammatory bowel disease in a nationwide database. Inflamm Bowel Dis 2017;23:875–881.CrossRef
8.
go back to reference Nguyen NH, Koola J, Dulai PS et al. Rate of risk factors for and interventions to reduce hospital readmission in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2020;18(19):1939–1948. Nguyen NH, Koola J, Dulai PS et al. Rate of risk factors for and interventions to reduce hospital readmission in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2020;18(19):1939–1948.
9.
go back to reference Limsrivilai J, Stidham RW, Govani SM et al. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2017;15:385-392 e2.CrossRef Limsrivilai J, Stidham RW, Govani SM et al. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2017;15:385-392 e2.CrossRef
10.
go back to reference Waljee AK, Lipson R, Wiitala WL et al. Predicting hospitalization and outpatient corticosteroid use in inflammatory bowel disease patients using machine learning. Inflamm Bowel Dis 2017;24:45–53.CrossRef Waljee AK, Lipson R, Wiitala WL et al. Predicting hospitalization and outpatient corticosteroid use in inflammatory bowel disease patients using machine learning. Inflamm Bowel Dis 2017;24:45–53.CrossRef
11.
go back to reference Snyder CF, Jensen RE, Segal JB et al. Patient-reported outcomes (PROs): putting the patient perspective in patient-centered outcomes research. Med Care 2013;51:S73–S79.CrossRef Snyder CF, Jensen RE, Segal JB et al. Patient-reported outcomes (PROs): putting the patient perspective in patient-centered outcomes research. Med Care 2013;51:S73–S79.CrossRef
12.
go back to reference Cohen ER, Melmed GY. Making a case for patient-reported outcomes in clinical inflammatory bowel disease practice. Clin Gastroenterol Hepatol 2018;16:603–607.CrossRef Cohen ER, Melmed GY. Making a case for patient-reported outcomes in clinical inflammatory bowel disease practice. Clin Gastroenterol Hepatol 2018;16:603–607.CrossRef
13.
go back to reference Singh S. PROMises made, PROMises to be kept: patient-reported outcome measures in inflammatory bowel diseases. Clin Gastroenterol Hepatol 2018;16:624–626.CrossRef Singh S. PROMises made, PROMises to be kept: patient-reported outcome measures in inflammatory bowel diseases. Clin Gastroenterol Hepatol 2018;16:624–626.CrossRef
14.
go back to reference Verma M, Stites S, Navarro V. Bringing assessment of patient-reported outcomes to hepatology practice. Clin Gastroenterol Hepatol 2018;16:447–448.CrossRef Verma M, Stites S, Navarro V. Bringing assessment of patient-reported outcomes to hepatology practice. Clin Gastroenterol Hepatol 2018;16:447–448.CrossRef
15.
go back to reference Kappelman MD, Long MD, Martin C et al. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014;12:1315–23 e2.CrossRef Kappelman MD, Long MD, Martin C et al. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014;12:1315–23 e2.CrossRef
16.
go back to reference Gracie DJ, Guthrie EA, Hamlin PJ et al. Bi-directionality of brain-gut interactions in patients with inflammatory bowel disease. Gastroenterology 2018;154:1635-1646 e3.CrossRef Gracie DJ, Guthrie EA, Hamlin PJ et al. Bi-directionality of brain-gut interactions in patients with inflammatory bowel disease. Gastroenterology 2018;154:1635-1646 e3.CrossRef
17.
go back to reference Gracie DJ, Williams CJ, Sood R et al. Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease. Am J Gastroenterol 2016;111:541–551.CrossRef Gracie DJ, Williams CJ, Sood R et al. Poor correlation between clinical disease activity and mucosal inflammation, and the role of psychological comorbidity, in inflammatory bowel disease. Am J Gastroenterol 2016;111:541–551.CrossRef
18.
go back to reference Kochar B, Barnes EL, Long MD et al. Depression Is associated with more aggressive inflammatory bowel disease. Am J Gastroenterol 2018;113:80–85.CrossRef Kochar B, Barnes EL, Long MD et al. Depression Is associated with more aggressive inflammatory bowel disease. Am J Gastroenterol 2018;113:80–85.CrossRef
19.
go back to reference Narula N, Pinto-Sanchez MI, Calo NC et al. Anxiety but not depression predicts poor outcomes in inflammatory bowel disease. Inflamm Bowel Dis 2019;25:1255–1261.CrossRef Narula N, Pinto-Sanchez MI, Calo NC et al. Anxiety but not depression predicts poor outcomes in inflammatory bowel disease. Inflamm Bowel Dis 2019;25:1255–1261.CrossRef
20.
go back to reference Long MD, Kappelman MD, Martin CF et al. Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis 2012;18:2099–2106.CrossRef Long MD, Kappelman MD, Martin CF et al. Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis 2012;18:2099–2106.CrossRef
21.
go back to reference Randell RL, Long MD, Cook SF et al. Validation of an internet-based cohort of inflammatory bowel disease (CCFA partners). Inflamm Bowel Dis 2014;20:541–544.CrossRef Randell RL, Long MD, Cook SF et al. Validation of an internet-based cohort of inflammatory bowel disease (CCFA partners). Inflamm Bowel Dis 2014;20:541–544.CrossRef
22.
go back to reference van Deen WKPD, Kwon MH, Blissett G, Crate DJ, Oberai R, Shah SA, Hwang C, Weaver SA, Siegel CA, Melmed GY. Validating patient reported utilization in the ibd qorus learning health system. Gastroenterology 2019;156:S11.CrossRef van Deen WKPD, Kwon MH, Blissett G, Crate DJ, Oberai R, Shah SA, Hwang C, Weaver SA, Siegel CA, Melmed GY. Validating patient reported utilization in the ibd qorus learning health system. Gastroenterology 2019;156:S11.CrossRef
23.
go back to reference Thia K, Faubion WA Jr, Loftus EV Jr et al. Short CDAI: development and validation of a shortened and simplified Crohn’s disease activity index. Inflamm Bowel Dis 2011;17:105–111.CrossRef Thia K, Faubion WA Jr, Loftus EV Jr et al. Short CDAI: development and validation of a shortened and simplified Crohn’s disease activity index. Inflamm Bowel Dis 2011;17:105–111.CrossRef
24.
go back to reference Jowett SL, Seal CJ, Phillips E et al. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol 2003;38:164–171.CrossRef Jowett SL, Seal CJ, Phillips E et al. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol 2003;38:164–171.CrossRef
25.
go back to reference Allegretti JR, Borges L, Lucci M et al. Risk factors for rehospitalization within 90 days in patients with inflammatory bowel disease. Inflamm Bowel Dis 2015;21:2583–2589.CrossRef Allegretti JR, Borges L, Lucci M et al. Risk factors for rehospitalization within 90 days in patients with inflammatory bowel disease. Inflamm Bowel Dis 2015;21:2583–2589.CrossRef
26.
go back to reference Hazratjee N, Agito M, Lopez R et al. Hospital readmissions in patients with inflammatory bowel disease. Am J Gastroenterol 2013;108:1024–1032.CrossRef Hazratjee N, Agito M, Lopez R et al. Hospital readmissions in patients with inflammatory bowel disease. Am J Gastroenterol 2013;108:1024–1032.CrossRef
27.
go back to reference Tinsley A, Naymagon S, Mathers B et al. Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors. Scand J Gastroenterol 2015;50:1103–1109.CrossRef Tinsley A, Naymagon S, Mathers B et al. Early readmission in patients hospitalized for ulcerative colitis: incidence and risk factors. Scand J Gastroenterol 2015;50:1103–1109.CrossRef
28.
go back to reference Feuerstein JD, Martinez-Vazquez M, Belkin E et al. 30 day readmissions rate and predictors of readmission in hospitalized patients with ulcerative colitis. Gastroenterology 2014;1:S-375.CrossRef Feuerstein JD, Martinez-Vazquez M, Belkin E et al. 30 day readmissions rate and predictors of readmission in hospitalized patients with ulcerative colitis. Gastroenterology 2014;1:S-375.CrossRef
29.
go back to reference Rizk M, Boules M, Michael M et al. Creation of a novel prospectively based inflammatory bowel disease readmission index. Am J Gastroenterol 2016;111:S265–S266.CrossRef Rizk M, Boules M, Michael M et al. Creation of a novel prospectively based inflammatory bowel disease readmission index. Am J Gastroenterol 2016;111:S265–S266.CrossRef
30.
go back to reference Amtmann D, Cook KF, Jensen MP et al. Development of a PROMIS item bank to measure pain interference. Pain 2010;150:173–182.CrossRef Amtmann D, Cook KF, Jensen MP et al. Development of a PROMIS item bank to measure pain interference. Pain 2010;150:173–182.CrossRef
31.
go back to reference Alexakis C, Kumar S, Saxena S et al. Systematic review with meta-analysis: the impact of a depressive state on disease course in adult inflammatory bowel disease. Aliment Pharmacol Ther 2017;46:225–235.CrossRef Alexakis C, Kumar S, Saxena S et al. Systematic review with meta-analysis: the impact of a depressive state on disease course in adult inflammatory bowel disease. Aliment Pharmacol Ther 2017;46:225–235.CrossRef
32.
go back to reference Szigethy E, Murphy SM, Ehrlich OG et al. Mental Health Costs of Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27(1):40–48. Szigethy E, Murphy SM, Ehrlich OG et al. Mental Health Costs of Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27(1):40–48.
Metadata
Title
Patient-Reported Outcomes and Risk of Hospitalization and Readmission in Patients with Inflammatory Bowel Diseases
Authors
Nghia H. Nguyen
Xian Zhang
Millie D. Long
William J. Sandborn
Michael D. Kappelman
Siddharth Singh
Publication date
10-06-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07082-3

Other articles of this Issue 6/2022

Digestive Diseases and Sciences 6/2022 Go to the issue

Editorial

BAM ≢ BAD